Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (361-370 of 636) with videos related to

Pageof 64
Sort By:
The New England Journal of Medicine|June 24, 2022
Fazirsiran for Liver Disease Associated with Alpha<sub>1</sub>-Antitrypsin DeficiencyPavel Strnad, Mattias Mandorfer, Gourab Choudhury, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 22, 2018
Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for CliniciansCeleste Allaband, Daniel McDonald, Yoshiki Vázquez-Baeza, et al.
Hepatology Communications|November 20, 2025
Association between pattern of hepatic iron deposition and severity of MASH among patients enrolled in the NASH Clinical Research NetworkAalam Sohal, Laura A Wilson, David E Kleiner, et al.
Contemporary Clinical Trials|July 24, 2017
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH studyA S Barritt, Norman Gitlin, Samuel Klein, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 19, 2013
Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjectsLindsey M Negrete, Michael S Middleton, Lisa Clark, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 26, 2018
Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitisNaga Chalasani, Manal F Abdelmalek, Rohit Loomba, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 12, 2024
Fibrosis, biomarkers and liver biopsy in AAT deficiency and relation to liver Z protein polymer accumulationAnandini Suri, Zidong Zhang, Brent Neuschwander-Tetri, et al.
Lancet (London, England)|December 18, 2018
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trialArun Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri, et al.
European Radiology|February 28, 2019
Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observationsCheng William Hong, Charlie C Park, Adrija Mamidipalli, et al.
Journal of Hepatology|October 22, 2019
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitisMohammad Shadab Siddiqui, Mark L Van Natta, Margery A Connelly, et al.
Pageof 64

Showing results (361-370 of 636) with videos related to

Sort By:
Pageof 64
The New England Journal of Medicine|June 24, 2022
Fazirsiran for Liver Disease Associated with Alpha<sub>1</sub>-Antitrypsin DeficiencyPavel Strnad, Mattias Mandorfer, Gourab Choudhury, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 22, 2018
Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for CliniciansCeleste Allaband, Daniel McDonald, Yoshiki Vázquez-Baeza, et al.
Hepatology Communications|November 20, 2025
Association between pattern of hepatic iron deposition and severity of MASH among patients enrolled in the NASH Clinical Research NetworkAalam Sohal, Laura A Wilson, David E Kleiner, et al.
Contemporary Clinical Trials|July 24, 2017
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH studyA S Barritt, Norman Gitlin, Samuel Klein, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 19, 2013
Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjectsLindsey M Negrete, Michael S Middleton, Lisa Clark, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 26, 2018
Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitisNaga Chalasani, Manal F Abdelmalek, Rohit Loomba, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 12, 2024
Fibrosis, biomarkers and liver biopsy in AAT deficiency and relation to liver Z protein polymer accumulationAnandini Suri, Zidong Zhang, Brent Neuschwander-Tetri, et al.
Lancet (London, England)|December 18, 2018
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trialArun Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri, et al.
European Radiology|February 28, 2019
Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observationsCheng William Hong, Charlie C Park, Adrija Mamidipalli, et al.
Journal of Hepatology|October 22, 2019
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitisMohammad Shadab Siddiqui, Mark L Van Natta, Margery A Connelly, et al.
Pageof 64